Clinical trial Recruiting at 2 sites Phase 3 Interventional Ages 30 to 100

Pilocarpine after cataract and Kahook goniotomy

Official title: A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade Surgery

Run by Montefiore Medical Center · NCT03933631 · Data updated 2026-11-12

This trial will test whether giving pilocarpine after combined cataract and Kahook Dual Blade surgery helps lower eye pressure and reduce the need for glaucoma medicines in people with open-angle glaucoma or ocular hypertension.

More Glaucoma trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages30 Years to 100 Years
SexAll
Enrollment142 (estimated)
SponsorMontefiore Medical Center
Academic / other
Locations2 sites (The Bronx, New York and 1 other locations)
StatusRecruiting
StartedMay 1, 2019
Main results expectedJune 2028
Study endsDecember 2028
Registry record updatedNovember 10, 2025
Trial IDNCT03933631 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with ocular hypertension or open-angle glaucoma who are scheduled for combined cataract surgery with Kahook Dual Blade goniotomy at Montefiore and have no prior eye surgeries are ideal candidates.

Probably not a fit

Patients with prior intraocular surgeries, other types of glaucoma not appropriate for KDB, or those who cannot tolerate pilocarpine side effects are unlikely to benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center Phase 3 interventional study enrolls patients having combined cataract surgery with Kahook Dual Blade goniotomy to see if adding postoperative pilocarpine improves surgical success. Participants receive standard postoperative care including topical steroid and antibiotic with pilocarpine added for the intervention group, and outcomes such as intraocular pressure and medication burden are tracked over follow-up. The Kahook procedure removes strips of trabecular meshwork to improve aqueous outflow, while pilocarpine acts by tightening the ciliary muscle and opening trabecular spaces. The trial is conducted at Montefiore with a single provider to standardize surgical technique and postoperative management.

Why it matters

Potential benefit: If successful, adding pilocarpine could further lower intraocular pressure after cataract+KDB surgery and reduce reliance on glaucoma medications.

How similar studies have gone: Pilocarpine is a well-known glaucoma drug but its routine postoperative use after KDB goniotomy is not well studied, and previous work on adjunctive medical therapies for MIGS has shown mixed results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with ocular hypertension or open angle glaucoma undergoing combined cataract surgery with KDB in a single surgical center at Montefiore Medical Center with a single provider

Exclusion Criteria:

* Patients with previous history of eye surgeries (including laser procedures)

Where it's running

  • Montefiore Wakefield Campus
    The Bronx, New York, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Wen-Jeng (Melissa) Yao, MD — Montefiore Medical Center
  • Study coordinator: Wen-Jeng (Melissa) Yao, MD
  • Email: WYAO@montefiore.org
  • Phone: 718-920-2020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.